Premium
Chemotherapy‐Induced Polyneuropathy: Major Agents and Assessment by Questionnaires
Author(s) -
Zedan Ahmed H.,
Vilholm Ole J.
Publication year - 2014
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.12262
Subject(s) - medicine , polyneuropathy , neuropathic pain , incidence (geometry) , chemotherapy , intensive care medicine , pharmacology , physics , optics
Chemotherapy‐induced polyneuropathy ( CIPN ) is a common, but underestimated, clinical challenge. Incidence varies depending on many factors that are equally as important as the type of chemotherapeutic agent itself. Moreover, the assessment of CIPN is still uncertain, as several of the most frequently used scales do not rely on a formal neurological evaluation and depend on patients’ reports and examiners’ interpretations. Therefore, the aim of this M ini R eview was to introduce the most common chemotherapies that cause neuropathy, and in addition to this, highlight the most significant differences between the neuropathic pain scales, which are most commonly used for assessing CIPN .